Biotherapeutics

#Biotherapeutics #Drug development #Drug discovery #Novel therapeutics

Infex’s resistance bypass drug program ready for clinic

Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through… Read More

#News

#Biotherapeutics #Drug development #Immunology / Virology & Vaccines #Vaccines

ENPICOM accelerates antibody and vaccine discovery

Viroclinics-DDL, a Contract Research Organisation (CRO) specialising in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines in vitro diagnostic and high-throughput sequencing… Read More

#News

#Biotechnology #Biotherapeutics #Drug development #Drug discovery #Therapeutics

1910 Genetics launches to accelerate therapeutics design

Biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, has launched after closing its $22 million Series A funding round. 1910 Genetics’ aim is to decrease the timeline and cost of drug development, while improving the success rate of getting medicines to patients. 1910 Genetics… Read More

#News

#Biotherapeutics #Coronavirus #Covid-19 #Drug development

Infex filed for UK patent for coronavirus novel therapy design

Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains. The COV-X program targets a protein which is essential for viral replication across a broad spectrum of related coronaviruses, including SARS-CoV-1, MERS-CoV and SARS-CoV-2. If successfully developed, the treatment aims to form… Read More

#Covid-19 #News

#Biologics / Biotechnology #Biotherapeutics #Cancer immunotherapy #Drug discovery

Bicara Therapeutics launches biologics for cancer immunotherapy

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumour microenvironment, launched with a US$40 million investment from Biocon. The financing will be used to advance a pipeline of first-in-class bifunctional antibodies developed by a global team, including a… Read More

#Cancer Research #News

#Biotherapeutics #Cell culture #Covid-19

Grant given to develop single and multi-organ models for COVID-19 research

CN Bio has received a grant from Innovate UK to develop human-relevant single and multi-organ microphysiological systems (MPS) to advance investigations into SARS-CoV-2 infection and advance 3D lung cell culture models to accelerate drug discovery. The grant will be spent developing and testing advanced cell culture models that represent different… Read More

#Covid-19 #News

#Biotherapeutics #Cancer research #Clinical Trial Authorisation

Avacta announces Phase I Clinical Trial Authorisation (CTA) for AVA6000

Avacta, the developer of Affimer biotherapeutics and reagents, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase I study of its lead pre|CISION pro-drug, AVA6000 pro-doxorubicin. In AVA6000, doxorubicin has been modified with Avacta’s pre|CISION… Read More

#Cancer Research #News

#Biotherapeutics #Microbiome #Oncology #Pharmaceuticals

4D pharma collaboration with Merck and Pfizer for urothelial carcinoma

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with… Read More

#Cancer Research #Editor's Choice #News

#Biopharmaceuticals #Biotherapeutics

Genedata and IDBS partnership streamlines biopharma discovery and development

Genedata and IDBS, have entered into a strategic partnership to create synergies between their platforms. The combined solution will directly integrate IDBS digital solutions with the Genedata Biopharma Platform so that all R&D as well as manufacturing data can be seamlessly exchanged, processed, and interpreted along the entire biopharma workflow. Read More

#News